PMID- 27236111
OWN - NLM
STAT- MEDLINE
DCOM- 20170811
LR  - 20220318
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 218
DP  - 2016 Sep 1
TI  - Digoxin and short term mortality after acute STEMI: Results from the MAGIC trial.
PG  - 176-180
LID - S0167-5273(16)30926-3 [pii]
LID - 10.1016/j.ijcard.2016.05.022 [doi]
AB  - BACKGROUND: The safety of digoxin has been a subject of debate for decades, most 
      recently among patients with atrial fibrillation (AF). Digoxin has been used 
      during the acute phase of ST elevation myocardial infarction (STEMI) complicated 
      with AF or heart failure. Data about digoxin in this setting are scarce. 
      HYPOTHESIS: We hypothesize that digoxin maybe associated with increased mortality 
      when used during the acute phase of ST segment myocardial infarction. METHODS: We 
      investigated the association between digoxin and mortality in patients enrolled 
      in the MAGnesium In Coronaries (MAGIC) study, which evaluated the efficacy of 
      early magnesium administration in STEMI. Multiple Cox proportional hazards models 
      were examined to assess the aforementioned association after correction for 
      clinical characteristics and comorbidities. RESULTS: After excluding 639 (10.3%) 
      patients for missing data, we analyzed the remaining 5574 patients. There were 
      852 (15.3%) deaths during the one month follow-up and 170 (3.0%) patients on 
      digoxin concomitantly, among which 42 patients (24.7%) died. There was a 
      statistically significant association between digoxin and increased mortality in 
      the unadjusted statistical analysis; however, this association disappeared after 
      correction for clinical characteristics and comorbidities in the primary 
      multivariable analysis (estimated hazard ratio [HR] 0.86, 95% confidence interval 
      [CI] 0.62-1.19, p=0.372) and in three additional multivariable analyses. 
      CONCLUSION: Digoxin use as a new or preexisting medication during the acute phase 
      of STEMI in the MAGIC trial was not associated with a significant increase in 
      mortality after correcting for clinical characteristics and comorbidities.
CI  - Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Metawee, Mohamed
AU  - Metawee M
AD  - University of Kentucky, Gill Heart Institute, Lexington, KY, United States; VAMC, 
      Cardiology, Lexington, KY, United States. Electronic address: 
      mohamed.metawee@gmail.com.
FAU - Charnigo, Richard
AU  - Charnigo R
AD  - University of Kentucky, Gill Heart Institute, Lexington, KY, United States; VAMC, 
      Cardiology, Lexington, KY, United States.
FAU - Morales, Gustavo
AU  - Morales G
AD  - University of Kentucky, Gill Heart Institute, Lexington, KY, United States; VAMC, 
      Cardiology, Lexington, KY, United States.
FAU - Darrat, Yousef
AU  - Darrat Y
AD  - University of Kentucky, Gill Heart Institute, Lexington, KY, United States; VAMC, 
      Cardiology, Lexington, KY, United States.
FAU - Sorrell, Vincent
AU  - Sorrell V
AD  - University of Kentucky, Gill Heart Institute, Lexington, KY, United States; VAMC, 
      Cardiology, Lexington, KY, United States.
FAU - Di Biase, Luigi
AU  - Di Biase L
AD  - University of Kentucky, Gill Heart Institute, Lexington, KY, United States; VAMC, 
      Cardiology, Lexington, KY, United States.
FAU - Natale, Andrea
AU  - Natale A
AD  - University of Kentucky, Gill Heart Institute, Lexington, KY, United States; VAMC, 
      Cardiology, Lexington, KY, United States.
FAU - Delisle, Brian
AU  - Delisle B
AD  - University of Kentucky, Gill Heart Institute, Lexington, KY, United States; VAMC, 
      Cardiology, Lexington, KY, United States.
FAU - Elayi, Claude S
AU  - Elayi CS
AD  - University of Kentucky, Gill Heart Institute, Lexington, KY, United States; VAMC, 
      Cardiology, Lexington, KY, United States.
CN  - and
AD  - University of Kentucky, Gill Heart Institute, Lexington, KY, United States; VAMC, 
      Cardiology, Lexington, KY, United States.
CN  - Magic investigators
AD  - University of Kentucky, Gill Heart Institute, Lexington, KY, United States; VAMC, 
      Cardiology, Lexington, KY, United States.
LA  - eng
PT  - Journal Article
DEP - 20160513
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 73K4184T59 (Digoxin)
RN  - 7487-88-9 (Magnesium Sulfate)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/*drug therapy
MH  - Digoxin/*administration & dosage/adverse effects
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Magnesium Sulfate/administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - ST Elevation Myocardial Infarction/drug therapy/*mortality
OTO - NOTNLM
OT  - Digoxin
OT  - Mortality
OT  - Myocardial infarction
EDAT- 2016/05/29 06:00
MHDA- 2017/08/12 06:00
CRDT- 2016/05/29 06:00
PHST- 2016/04/12 00:00 [received]
PHST- 2016/05/12 00:00 [accepted]
PHST- 2016/05/29 06:00 [entrez]
PHST- 2016/05/29 06:00 [pubmed]
PHST- 2017/08/12 06:00 [medline]
AID - S0167-5273(16)30926-3 [pii]
AID - 10.1016/j.ijcard.2016.05.022 [doi]
PST - ppublish
SO  - Int J Cardiol. 2016 Sep 1;218:176-180. doi: 10.1016/j.ijcard.2016.05.022. Epub 
      2016 May 13.